This morning, LSD drug developer Definium Therapeutics shared positive topline data from its second Phase 3 study of its lead candidate, DT120, in generalised anxiety disorder (GAD). It’s the third positive Phase 3 readout from the company since June. The trial, dubbed Panorama, saw 245 participants across around 32 U.S. and international sites randomised to receive a single dose of 100 µg…
